Age, Not Polyp Size, Predicts Cancer Risk in Endometrial Polyps - A 740-Case Analysis

Endometrial polyps are among the most frequently encountered findings in gynecological practice. They appear in women of all ages presenting with abnormal uterine bleeding, and the clinical question they consistently raise is the same: how worried should a clinician be about malignancy?

A retrospective analysis of 740 endometrial polyps diagnosed between 2021 and 2022 provides some of the clearest data available on that question. Published in a peer-reviewed journal, the study found that the overall malignancy rate among these polyps was 4%, with a further 2% showing premalignant changes. More importantly, it identifies which clinical features actually predict that elevated risk - and which ones do not.

The 740-Case Dataset

Among the 740 polyp cases analyzed, 94% were benign, 2% showed premalignant changes, and 4% were malignant. The median patient age across all cases was 54 years, with a range from 19 to 92. The most prevalent cancer type among the malignant polyps was minimal serous carcinoma (14 cases, 2%), a finding with important implications for pathological evaluation given the known aggressive behavior of serous endometrial carcinoma even at minimal involvement.

Immunohistochemistry for p53 and p16 was performed on 52 selected cases. Among these, 38 cases diagnosed as benign showed wild-type p53 staining patterns, while 14 cases with serous carcinoma showed mutant p53 patterns - supporting the known association between p53 mutation and serous endometrial carcinoma and validating the use of p53 immunohistochemistry as a diagnostic adjunct in ambiguous cases.

What Predicts Malignancy - and What Does Not

Statistical analysis identified two factors significantly associated with malignant polyps: advanced patient age and malignant background endometrium (p less than 0.001 for both). The background endometrium is the uterine lining surrounding the polyp, and its histological status appears to be a more important predictor of polyp malignancy than the polyp itself in isolation.

Neither polyp size nor polyp recurrence showed significant association with malignancy risk. These findings challenge assumptions that may influence clinical management decisions. Larger polyps are sometimes presumed to carry higher cancer risk and may prompt more aggressive follow-up or intervention. The data here suggest that size alone is an unreliable guide to malignancy probability.

Similarly, recurrent polyps - those that develop again after polypectomy - are not at significantly higher risk of malignancy than primary polyps in this dataset. Recurrence may have other clinical implications, but it does not appear to be a marker of increased cancer risk.

Implications for Pathological Practice

The study makes specific practical recommendations based on these findings. The observation that malignant background endometrium strongly predicts polyp malignancy underscores the importance of routinely sampling the endometrial tissue surrounding a polyp at the time of polypectomy, rather than submitting only the polyp itself for histological analysis. Sampling only the polyp risks missing occult premalignant or malignant changes in adjacent tissue.

This recommendation is particularly important in postmenopausal patients, where the baseline risk of endometrial pathology is higher and where abnormal uterine bleeding carries greater significance as a warning sign. Endometrial sampling in postmenopausal patients undergoing polypectomy is advocated strongly in the study's conclusions.

For patients over 65 years of age, where malignancy risk was most pronounced, the study recommends consideration of p53 immunohistochemistry and additional endometrial sampling to aid in the early detection of serous carcinoma. This targeted use of immunohistochemistry - applied to high-risk patients rather than universally - represents a practical resource allocation strategy for pathology departments.

Limitations and Context

The study is retrospective, drawing on an existing pathology database from cases diagnosed over a two-year period. Retrospective designs have inherent limitations: case selection is not randomized, clinical management decisions that preceded the pathological findings may have introduced selection bias, and the population may not be representative of other clinical settings.

The two-year observation window does not allow for long-term follow-up data on patients with benign polyps, so the study cannot address the question of what proportion of initially benign polyps develop malignancy over subsequent years. Prospective studies with longer follow-up would be needed to address that question fully.

The overall malignancy rate of 4% provides useful context for clinical counseling: while most endometrial polyps are benign, the risk of malignancy is not negligible, particularly in older postmenopausal patients where the risk profile is substantially higher than the population average. Age-stratified risk estimates, if available from this dataset, would be valuable for individualized patient counseling.